IN8bio (INAB) investor relations material

Executive summary

• Focused on gamma-delta (yō) T cell therapies for cancer and autoimmune diseases, with lead programs INB-100 (AML) and INB-200/400 (glioblastoma) in clinical development.

• Advanced yō T cell engager platform with promising preclinical results; initial in vivo data for INB-619 expected in H2 2026.

• Presented updated clinical data showing median overall survival exceeding 19.5 months in newly diagnosed glioblastoma patients treated with DeltEx DRI.

• INB-100 Phase 1 enrollment completed; expansion cohort ongoing, with clinical update expected late 2026.

• INB-200/400 Phase 1 completed; INB-400 Phase 2 enrollment suspended to conserve capital, with ongoing data follow-up.

Financial highlights

• Cash balance of $18.0 million as of June 30, 2026, up from $13.2 million year-over-year, but down from $27.1 million at year-end 2025.

• Net loss for Q2 2026 was $4.8 million ($0.25 per share), improved from $5.1 million ($1.24 per share) in Q2 2025; six-month net loss $9.9 million vs. $10.6 million prior year.

• Operating expenses for Q2 2026 were $4.9 million, down from $5.2 million in Q2 2025; R&D expenses for Q2 2026: $2.5 million, flat year-over-year.

• No revenue generated; interest income increased to $0.2 million for Q2 2026.

Outlook and guidance

• Current cash expected to fund operations through April 2027; substantial doubt exists about ability to continue as a going concern without additional capital.

• Management pursuing additional funding via equity/debt offerings, warrant exercises, and strategic collaborations.

• Up to $20.1 million in additional proceeds possible from milestone-driven warrant exercises, but not assured.

• Initial in vivo preclinical data for INB-619 expected in H2 2026; clinical update for INB-100 program planned for late 2026.